Adc Therapeutics SA 10-Q quarterly reports

ADC Therapeutics reported a 15.1% increase in net product revenue for Q1 2026, driven by higher sales volume and pricing, while R&D expenses decreased significantly due to restructuring.

ADC Therapeutics reported a wider net loss in Q3 2025, driven by restructuring costs, despite strong clinical trial data for ZYNLONTA and successful capital raises.

ADC Therapeutics reported a widened net loss in Q2 2025, driven by a strategic restructuring plan and increased R&D costs, despite a rise in ZYNLONTA product and license revenues.

ADC Therapeutics' Q1 2025 results show increased revenue driven by licensing milestones, alongside ongoing efforts to manage operating expenses and advance its ADC technology.

ADC Therapeutics reported its third quarter 2024 financial results, showing a slight increase in product revenue and a decrease in operating expenses.

ADC Therapeutics reported its second quarter 2024 financial results, showcasing a decrease in product revenue but progress in its clinical pipeline and research strategy.

ADC Therapeutics reported a net loss of $46.6 million for the first quarter of 2024, with product revenue slightly decreasing to $17.8 million.